These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 9816630
1. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12). Freibauer C. Wien Klin Wochenschr; 1998 Sep 18; 110(17):608-11. PubMed ID: 9816630 [Abstract] [Full Text] [Related]
2. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Weinstein MH, Signoretti S, Loda M. Mod Pathol; 2002 Dec 18; 15(12):1302-8. PubMed ID: 12481011 [Abstract] [Full Text] [Related]
3. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate. Botticelli AR. Pathologica; 1994 Apr 18; 86(2):128-41. PubMed ID: 7524011 [Abstract] [Full Text] [Related]
4. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma. Leav I, Schelling KH, Adams JY, Merk FB, Alroy J. Prostate; 2001 May 15; 47(3):149-63. PubMed ID: 11351344 [Abstract] [Full Text] [Related]
5. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Sinha AA, Quast BJ, Reddy PK, Lall V, Wilson MJ, Qian J, Bostwick DG. Exp Mol Pathol; 2004 Oct 15; 77(2):153-9. PubMed ID: 15351240 [Abstract] [Full Text] [Related]
7. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Wojno KJ, Epstein JI. Am J Surg Pathol; 1995 Mar 15; 19(3):251-60. PubMed ID: 7532918 [Abstract] [Full Text] [Related]
8. Benign mimics of prostatic adenocarcinoma on needle biopsy. Gaudin PB, Reuter VE. Anat Pathol; 1997 Mar 15; 2():111-34. PubMed ID: 9575372 [Abstract] [Full Text] [Related]
13. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Mirtti T, Alanen K, Kallajoki M, Rinne A, Söderström KO. Prostate; 2003 Mar 01; 54(4):290-8. PubMed ID: 12539227 [Abstract] [Full Text] [Related]
16. Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Cancer; 1996 Jul 15; 78(2):376-81. PubMed ID: 8674022 [No Abstract] [Full Text] [Related]
17. Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H. Ann Diagn Pathol; 2006 Aug 15; 10(4):205-8. PubMed ID: 16844561 [Abstract] [Full Text] [Related]
18. [Premalignant and benign lesions in nodules of adenomatous hyperplasia]. Miján Ortiz JL, Fernández Rodríguez A, Fernández Ruiz PL, de la Fuente Serrano A, Nogales Fernández F, Zuluaga Gómez A. Arch Esp Urol; 1996 Sep 15; 49(7):684-7. PubMed ID: 9020004 [Abstract] [Full Text] [Related]
19. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate. Rekhi B, Jaswal TS, Arora B. Indian J Cancer; 2004 Sep 15; 41(2):60-5. PubMed ID: 15318010 [Abstract] [Full Text] [Related]
20. Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma. Netto GJ, Epstein JI. Am J Surg Pathol; 2006 Sep 15; 30(9):1184-8. PubMed ID: 16931964 [Abstract] [Full Text] [Related] Page: [Next] [New Search]